CoChat

Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma

Lee, Nuri, Lee, Jae Lyun, Lee, Ju-Yeun · 2023 · Targeted Oncology

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background Limited studies have evaluated anti-angiogenesis-related adverse events involving oral vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in metastatic renal cell carcinoma using real-world data. Objective This study aimed to investigate the incidence, patterns, and impact on the dose intensity of anti-angiogenesis-related adverse events associated with the use of VEGFR-TKIs in patients with metastatic renal cell carcinoma using real-world data. Methods This cross-sectional study included patients with a diagnosis of metastatic renal cell carcinoma who received axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib at a tertiary hospital in South Korea. We categorized the patients into those who had not previously received a VEGFR-TKI (VEGFR-TKI-naive) and those who had previously received a VEGFR-TKI (VEGFR-TKI-experienced). Anti-angiogenesis-related adverse events were defined as hypertension, proteinuria, bleeding, thrombosis, hypothyroidism, and left ventricular dysfunction, which were rated "possible" or higher based on a causality assessment scale. Results Among a total of 988 patients, 674 patients were VEGFR-TKI-naïve and 314 patients were VEGFR-TKI-experienced. Anti-angiogenesis-related adverse events of any grade and severe adverse events occurred in 65.1 and 34.6% of VEGFR-TKI-naïve patients and 54.8 and 36.0% of VEGFR-TKI-experienced patients, respectively. Regardless of treatment history, the most common adverse ev…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11523-023-00951-z

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 20

Metadata

Authors
Lee, N., Lee, J. L., & Lee, J.-Y.
Affiliations
Seoul National University (KR)
Corresponding author
  • Lee, Jae Lyun
  • Lee, Ju-Yeun
Venue
Targeted Oncology
Published
2023-02-24
Volume
18
Issue
2
Pages
247-255
ISSN
  • 1776-2596 (ISSN-L)
  • 1776-260X
OpenAlex
W4321748343
Cited by
20
References
21
Citations by year
2026: 5 · 2025: 7 · 2024: 4 · 2023: 4
FWCI
3.67
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Targeted Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
metastatic renal cell carcinoma, VEGFR inhibitors, hypertension, proteinuria, hemorrhage, thrombosis, hypothyroidism, left ventricular dysfunction, dose intensity, axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, real-world data, adverse event incidence
MeSH terms
Sorafenib, Tyrosine Kinase Inhibitors, Antineoplastic Agents, Carcinoma, Renal Cell, Cross-Sectional Studies, Humans, Hypertension, Kidney Neoplasms, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1007/s11523-023-00951-z
The paper
Lee, N., Lee, J. L., & Lee, J.-Y. (2023). Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma. Targeted Oncology. https://doi.org/10.1007/s11523-023-00951-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.